NCT03557658View on ClinicalTrials.gov

Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 26, 2018

Primary Completion Date

December 26, 2018

Study Completion Date

December 26, 2018

Conditions
Type2 Diabetes Mellitus
Interventions
DRUG

Bexagliflozin

Single oral dose of bexagliflozin tablet, 20 mg

Trial Locations (2)

55114

Clinical Research Site 2, Saint Paul

02114

Clinical Research Site 1, Boston

Sponsors

Lead Sponsor

Theracos
All Listed Sponsors
lead

Theracos

INDUSTRY

NCT03557658 - Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment | Biotech Hunter | Biotech Hunter